Skip to main content
. Author manuscript; available in PMC: 2013 Nov 7.
Published in final edited form as: J Clin Oncol. 2004 Nov 1;22(21):10.1200/JCO.2004.09.096. doi: 10.1200/JCO.2004.09.096

Table 4.

Fenretinide (4-HPR) and 4-MPR Pharmacokinetic Parameters

No. of
Patients		 Dose
(mg/m2)		 Cpmax (ng/mL) AUC0–12 h (µg × h/mL) Decrease in Retinol
4-HPR 4-MPR 4-HPR 4-MPR
Value SD Value SD Value SD Value SD % SD Range
26 600 832 360 232 125 5.84 2.47 1.64 0.93 45.83 10.05* 25%–67%
4 900 1213 261 337 113 8.60 2.17 2.45 0.83 50.33 5.03† 45%–55%

NOTE. Cpmax and AUC0–12 h reflective of 600 or 900 mg/m2 single administration. Retinol levels were assessed at baseline and 24 hours after fenretinide was first administered.

Abbreviations: 4-MPR, N-(4-methoxyphenyl)-retinamide; Cpmax, peak concentration; AUC, area under the concentration-time curve; SD, standard deviation.

*

n = 23

†

n = 3.